

## Bora Pharmaceuticals Reports Consolidated Revenue of NT\$2.11 Billion in May

### 保瑞公告 5 月自結合併營收新台幣 21 億 1 仟萬元

Taipei, Taiwan, June 8, 2026 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for May 2026 reached NT\$2.11 billion. May revenues grew 40.19% year-over-year, while the cumulative year-to-date decline narrowed to 9.11%.

台北，台灣，2026 年 6 月 8 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 5 月自結合併營收為新台幣 21 億 1 仟萬元，5 月營收較去年同期大幅增長 40.19%，今年累計營收衰退收斂至 9.11%。

Weider Global Nutrition (“Weider”) was consolidated from its closing date on May 5 and benefited from the U.S. retail promotional season. Excluding Weider, CDMO revenues, including internal orders, rose 41.27% over the monthly average of the previous quarter and grew 16.06% against April, marking the highest monthly revenues outside the traditional year-end high season and the third highest on record, with utilization improving markedly sequentially. In pharma sales, flagship generic product DLS successfully defended its market share and stabilized, while leading specialty drug VIGAFYDE<sup>®</sup> momentum continued.

本月 Weider Global Nutrition（下稱威德）自 5 日交割日起併表且受惠美國零售促銷旺季貢獻，若排除威德營收，CDMO 業務營收較第一季月均提升 41.27%且較 4 月成長 16.06%，創下非第四季傳統旺季的最高月營收且為史上第三高，稼動率明顯前一季提升；而全球銷售業務主力學名藥產品 DLS 成功守住市占，表現趨於穩定，旗艦專科用藥 VIGAFYDE<sup>®</sup> 營收亦持續上攻。

Bora Group Chairman Bobby Sheng noted that the past 12 months had been eventful as the Company integrated its early-stage U.S. operations and adjusted strategy in response to macro and geopolitical volatility. With a multi-billion-dollar long-term agreement signed with a major Top-20 pharma client and its CDMO capability platform now in place, Bora is entering a new, more disciplined phase of expansion. "Over the past year, Bora executed a large-scale, cross-border integration program from closing the Minnesota production area in Plymouth, undertaking our highest capital expenditure in response to the reshoring of U.S. pharmaceutical supply chains, to completing the repositioning of our Maple Grove site from transitional handover to delivering organic growth," he said. "Financial performance through the integration phase was in line with Management expectations, with cash quality substantially improved versus 2024. As a group, we have advanced our strategy according to plan, and the team's near-term objective this quarter is to drive synergies between our new biologics CDMO assets and the existing platform."

保瑞集團董事長盛保熙指出，過去 12 個月因整合美國業務以及因應市場波動調整策略，公司度過了較為辛苦的一段時間，然隨著重磅客戶百億長約簽約以及 CDMO 技術布局到位，保瑞將進入更有紀律的擴張新階段；他說：「過去一年，保瑞執行了大規模的跨國整合計畫，包括關閉明尼蘇達州 Plymouth 生

產區域、回應美國製藥行業供應鏈回流進行有史以來最高的資本支出，並完成 Maple Grove 廠區從過渡接手到自主成長的定位轉型。整合期間的財務表現在預期之內，且現金品質較 2024 年大為提升，管理層始終按既定藍圖推進策略，團隊本季度的短期目標為朝著創造生物製劑 CDMO 新資產與既有平台的綜效前進。」

Bora also announced its honored as one of TIME's World's Most Impactful Companies 2026, the international leading magazine's list of 500 of the world's most influential enterprises. The honorees span technology, energy, finance, and healthcare worldwide, with 12 Taiwanese companies named. The recognition reflects growing international affirmation of the Group's sustained commitment to expanding patient access to medicines, strengthening global supply-chain resilience, and broadening its health impact through its global pharmaceutical platform and sustainability strategy.

保瑞今日亦宣布獲選為國際領導雜誌《TIME》2026 全球最具影響力 500 強企業之一（TIME World's Most Impactful Companies 2026），獲獎榜單涵蓋全球科技、能源、金融與醫療健康等多元產業，全台共有 12 家企業入選，足見集團持續透過布局國際製藥平台與貫徹永續發展策略，致力提升病患藥物可近性、強化全球供應鏈韌性以及擴大健康影響力等面向的長期投入已逐步獲得國際市場肯定。

#### About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW and BORAY.OTCQX) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

#### 關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472.TW與BORAY.OTCQX）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>



CDMO 網站 <https://www.boracdmo.com>

**Investor/Media enquiries 新聞聯繫人：**

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email : [Nadiya.Chen@bora-corp.com](mailto:Nadiya.Chen@bora-corp.com)